Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
about
Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyondGenomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients.A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.Telomere status in chronic lymphocytic leukemia with TP53 disruption.Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutationsLongitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive diseaseExtensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlationsTP53 Gene Status Affects Survival in Advanced Mycosis Fungoides.The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.Chronic lymphocytic leukaemia genomics and the precision medicine era.CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons.Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia.Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.In-vitro and in-vivo evidence for uncoupling of BCR internalization and signaling in chronic lymphocytic leukemia.Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in noSomatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry.Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia.Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease.Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.NOTCH1 Aberrations in Chronic Lymphocytic Leukemia.Chronic lymphocytic leukaemia
P2860
Q27027493-5E789CB5-8D9A-478F-AD65-6EB68BE8807BQ30833823-39060B81-C402-457D-BB41-0342427C3AD1Q34545956-F0760B79-3115-4111-843A-CF6DD98A8562Q35984259-0640A224-7240-42E7-B2F8-A67287D78262Q36093789-F7655986-E1DB-4ED5-B912-3FF1B74501FEQ36622188-C6FE1EEB-ADCB-465C-BA99-204CB5CB845CQ36884141-71AF434B-F597-4A3A-A171-FA837D7D0F46Q37260520-BAEA3EB9-6459-48CD-AED8-0531C6FFF29EQ37407941-9BFB7D72-0D82-4545-9262-DFA61C9408C6Q38719429-3DAB8F01-B572-4255-A89A-DAD66A0F5F10Q38744632-79CAC9AC-057E-4D58-9E6C-B0E6D2A6754DQ38754419-EC8CE010-B2D4-46CA-A7FD-AB7401216863Q38997367-E9750EB1-7E74-41DC-A906-CD0DEB131CD3Q39039713-65C091F8-005C-4CA1-B23B-E3611DAE76DFQ39263974-A97B8B62-C0B6-4835-8E7B-38D77C081325Q40784167-73E14001-3D03-4053-9A9F-A2FD13E0FAB0Q42378526-A2EA89CF-8C24-4EC6-B4FF-CD4794D5D83EQ42923891-8E002D7E-3173-49E6-A523-C6464CBD201CQ47995370-4585E8D1-963B-46D9-ACBE-D34D795C0E4CQ48264151-70BC7388-020B-4390-86B1-64FD79910615Q49837442-F420EE8E-638D-46B7-A1F6-8861B839985AQ50025029-D926958A-9087-40D2-89C0-CD2F7365DFCFQ51216583-9A835BBE-4B35-40FA-A4DD-9E70675335ACQ52796916-81F27480-3D19-4BDE-8E76-B31B20B46C97Q54977441-B7D3D371-082D-4696-B0E7-6D7741D1460EQ55182677-649C086E-AB0D-4CE0-A0F3-5BC87168D810Q55644886-FFFECF74-3F5B-4E70-9E82-2E70F92D78E4Q55668973-B8D02196-BB62-44A1-902A-72F92DEB740DQ56270980-DC352E6D-4FD5-44C6-93BB-AB65B02B3CE4
P2860
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Presence of multiple recurrent ...... me of relapsed/refractory CLL.
@en
Presence of multiple recurrent ...... me of relapsed/refractory CLL.
@nl
type
label
Presence of multiple recurrent ...... me of relapsed/refractory CLL.
@en
Presence of multiple recurrent ...... me of relapsed/refractory CLL.
@nl
prefLabel
Presence of multiple recurrent ...... me of relapsed/refractory CLL.
@en
Presence of multiple recurrent ...... me of relapsed/refractory CLL.
@nl
P2093
P50
P1433
P1476
Presence of multiple recurrent ...... ome of relapsed/refractory CLL
@en
P2093
Adele Timbs
Andrew Pettitt
Angela Hamblin
Anna Schuh
Frédéric Davi
Joanne Mason
Loïc Ysebaert
Maite Cabes
Marie-Sarah Dilhuydy
Olivier Tournilhac
P304
P356
10.1182/BLOOD-2015-05-647578
P407
P50
P577
2015-08-27T00:00:00Z